Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.660
+0.150 (3.33%)
At close: Feb 2, 2026, 4:00 PM EST
4.610
-0.050 (-1.07%)
After-hours: Feb 2, 2026, 7:48 PM EST
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.28 billion as of February 2, 2026. Its market cap has increased by 282.11% in one year.
Market Cap
1.28B
Enterprise Value
1.05B
1-Year Change
282.11%
Ranking
Category
Stock Price
$4.66
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.28B, an increase of 84.88%. That is a compound annual growth rate of 12.16%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 30, 2026 | 1.24B | -18.00% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Trevi Therapeutics | 1.34B |
| DBV Technologies | 1.33B |
| Relay Therapeutics | 1.33B |
| AnaptysBio | 1.31B |
| Savara | 1.30B |
| Immatics | 1.28B |
| Rapport Therapeutics | 1.27B |
| Xeris Biopharma Holdings | 1.22B |